Unjha Formulations Peer Comparison

BSE: 531762

₹33.90

₹1.30 (3.99%)

As on 09-Oct-2026IST

Market cap

₹15 Cr

Revenue (TTM)

₹15 Cr

P/E Ratio

32.3

P/B Ratio

3.8

Div. Yield

0 %

Edit

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Piramal Pharma
Market cap (₹ Cr)	15	34,811	32,453	26,789	26,181
Revenue (₹ Cr)	15	9,683	3,564	2,372	9,205
Net Profit (₹ Cr)	0.47	1,018.97	414.00	497.77	-371.81
Net Margin (%)	3.05	10.47	11.23	20.72	-3.93
RoE (%)	11.48	21.30	8.38	28.49	-3.85
Price to Earnings	32.32	34.42	79.35	53.82	--
Price-To-Book	3.80	6.66	6.45	13.25	3.27

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Piramal Pharma
Operating Revenue	15.42	9,683.45	3,564.00	2,371.81	9,205.28
Total Income	15.42	9,730.84	3,686.00	2,402.61	9,449.59
Total Expenditure	14.55	7,739.53	2,792.00	1,608.91	8,195.15
EBITDA	0.88	1,943.92	772.00	762.90	1,010.13
Depreciation	0.15	425.10	226.00	98.11	857.51
EBIT	0.73	1,518.82	546.00	664.79	152.62
Interest	0.01	148.45	217.00	26.33	342.73
Other Income	0.00	47.39	122.00	30.80	244.31
Exceptional Items	0.00	-27.85	12.00	0.00	-216.88
Profit before Tax	0.72	1,389.91	463.00	669.26	-162.68
Provision for Tax	0.25	370.94	49.00	171.48	209.13
Profit after Tax	0.47	1,018.97	414.00	497.77	-371.81

Liabilities (₹ Cr)

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Piramal Pharma
Shareholder's Funds	3.84	4,950.03	4,940.00	1,874.47	8,162.62
Minority Interest	0.00	-7.58	-5.00	0.00	0.00
Non-Current Liabilities	0.00	723.57	1,712.00	345.47	5,044.14
Current Liabilities	1.67	3,912.24	1,622.00	710.20	4,758.28
Total Liabilities	5.51	9,514.48	8,578.00	2,930.14	17,723.32

Assets (₹ Cr)

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Piramal Pharma
Non-Current Assets	1.30	3,392.16	5,343.00	1,290.62	10,211.52
Current Assets	4.21	5,612.10	2,606.00	1,483.13	7,191.66
Total Assets	5.51	9,514.48	8,578.00	2,930.14	17,723.32
Total Debt*	0.00	1,204.08	2,125.00	196.61	5,495.48
Net Current Assets	2.55	1,699.86	984.00	772.93	2,433.38
Contingent Liabilities	8.80	258.92	768.26	13.18	95.72

Cashflow (₹ Cr)

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Piramal Pharma
Cash From Operating Activities	1.24	943.55	390.00	346.68	1,652.60
Cash Flow from Investing Activities	-0.23	-1,193.06	-241.00	-423.73	-826.03
Cash from Financing Activities	-0.01	343.43	-54.00	20.98	-38.98
Net Cash Inflow / Outflow	1.00	93.92	95.00	-56.08	787.59

Ratios

Profitability Ratios

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Piramal Pharma
ROCE (%)	27.54	25.25	6.79	27.50	1.24
ROE (%)	11.48	21.30	8.38	28.49	-3.85
ROA (%)	9.34	11.42	4.94	19.48	-2.21
EBIT Margin (%)	4.71	15.68	15.32	28.03	1.66
Net Margin (%)	3.05	10.47	11.23	20.72	-3.93
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Piramal Pharma
Revenue Growth (%)	12.94	18.36	18.37	78.33	0.78
EBIT Growth (%)	231.51	30.43	252.26	303.07	-70.53
Net Profit Growth (%)	379.59	32.39	377.85	182.61	-1,383.43
EPS Growth (%)	379.59	36.68	1,001.33	277.72	-484.84
Book Value Growth (%)	22.45	11.36	13.47	22.95	0.33

Valuation Ratios

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Piramal Pharma
Price / Earnings	32.32	33.71	81.44	53.82	-83.67
Price / Book Value	3.80	6.66	6.45	13.25	3.27
Dividend Yield (%)	0.00	0.20	0.00	0.16	0.00
EV/EBITDA	15.46	18.45	43.93	34.91	30.02
Market Cap (₹ Cr)	9.09	30,257.56	19,071.62	15,412.11	18,108.89

Solvency Ratios

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Piramal Pharma
Debt to Equity	0.00	0.05	0.31	0.09	0.53
Short term debt to equity ratio	--	0.16	0.09	--	0.09
Current Ratio	2.53	1.43	1.61	2.09	1.51
Quick Ratio	2.15	0.82	1.06	1.37	0.87
Interest Coverage	103.71	10.36	3.13	26.41	0.53

Operating Efficiency Ratios

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Piramal Pharma
Debtors to sales (%)	8.74	26.46	16.50	22.82	23.44
Asset Turnover	3.06	1.09	0.43	0.93	0.55
Receivable days	33.45	88.68	58.75	77.32	78.20
Inventory Days	19.48	84.11	75.82	80.83	93.30
Payable days	37.68	176.65	186.21	125.94	226.14
Cash Conversion Cycle	15.25	-3.86	-51.64	32.22	-54.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly